Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Hans L. Tillmann & Gbeminiyi Samuel. (2019) Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. Expert Opinion on Pharmacotherapy 20:7, pages 873-885.
Read now
Read now
Harriet F Lamont, Henrietta J Blogg & Ronald F Lamont. (2014) Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opinion on Drug Safety 13:12, pages 1569-1581.
Read now
Read now
Jörg Petersen & Maria Buti. (2012) Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Review of Gastroenterology & Hepatology 6:6, pages 683-694.
Read now
Read now
Michael P Manns, Ulus S Akarca, Ting-Tsung Chang, William Sievert, Seung Kew Yoon, Naoky Tsai, Albert Min, Andreas Pangerl, Suzanne Beebe, Miao Yu & Suchat Wongcharatrawee. (2012) Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opinion on Drug Safety 11:3, pages 361-368.
Read now
Read now
Articles from other publishers (19)
N HASSAN, FU AMIN, K BASHIR, M IRSHAD, S JAMIL, N MUNAWAR, H HAQQANI, H SHABIR & MA KHAN. (2023) ANTIVIRAL RESPONSE OF DRUGS USED AGAINST HBV PATIENTS OF KHYBER PAKHTUNKHWA, PAKISTAN. Bulletin of Biological and Allied Sciences Research 2023:1, pages 49.
Crossref
Crossref
Min-Yu Lan, Hui-Chen Lin, Tsung-Hui Hu, Shu-Fang Chen, Chien-Hung Chen, Yung-Yee Chang, King-Wah Chiu, Tsu-Kung Lin & Shun-Sheng Chen. (2023) Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors. Journal of Clinical Neurology 19:1, pages 52.
Crossref
Crossref
Xiuhan Yang, Xiaozhu Zhong, Huihua Liao & Yongchang Lai. (2020) Efficacy of antiviral therapy during the second or the third trimester for preventing mother-to-child hepatitis B virus transmission: a systematic review and meta-analysis. Revista do Instituto de Medicina Tropical de São Paulo 62.
Crossref
Crossref
Ahmed Elsanhoury, Sophie Van Linthout & Carsten Tschöpe. 2020. Myocarditis. Myocarditis
297
316
.
Long Jianfei, Wang Min, Ma Chunlai, Chen Bicui, Zhang Jiming & Wang Bin. (2017) The Ca 2+ /CaMKK2 axis mediates the telbivudine induced upregulation of creatine kinase: Implications for mechanism of antiviral nucleoside analogs’ side effect. Biochemical Pharmacology 146, pages 224-232.
Crossref
Crossref
W. Yi, M.-H. Li, Y. Xie, J. Wu, Y.-H. Hu, D. Zhang, Y. Zhang & W.-H. Cao. (2017) Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus. Journal of Viral Hepatitis 24, pages 49-56.
Crossref
Crossref
Jia-Horng Kao, Tarik Asselah, Xiao-Guang Dou & Kamal Hamed. (2017) Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. Journal of Gastroenterology and Hepatology 32:1, pages 73-81.
Crossref
Crossref
Ilker Turan, Suna Yapali, Fikret Bademkiran, Timur Kose, Soner Duman, Murat Sozbilen, Fulya Gunsar, Galip Ersoz, Ulus Salih Akarca, Omer Ozutemiz & Zeki Karasu. (2015) Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy. Liver Transplantation 21:8, pages 1066-1075.
Crossref
Crossref
Huihui Zeng, Haodong Cai, Ying Wang & Ying Shen. (2015) Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers. International Journal of Infectious Diseases 33, pages 97-103.
Crossref
Crossref
Kai Yuan, Wang Guochun, Zhenguo Huang, Bing Lin, Huiqiong Zhou & Xin Lu. (2014) Entecavir-associated myopathy: A case report and literature review. Muscle & Nerve 49:4, pages 610-614.
Crossref
Crossref
S. W. Lee, J. H. Jang & B. J. Kim. (2013) Dysphagia could be the first presenting symptom of telbivudine-induced myopathy. Internal Medicine Journal 43:9, pages 1048-1049.
Crossref
Crossref
Lai Wei, Shanlian Hu, Jinlin Hou, Gordon Liu, Hong Ren, Zhongping Duan, Qing Xie, Xiao Fang & Jidong Jia. (2013) A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. Value in Health Regional Issues 2:1, pages 48-56.
Crossref
Crossref
M. Liu, H. Cai & W. Yi. (2013) Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. Journal of Viral Hepatitis 20, pages 65-70.
Crossref
Crossref
Jun Yong Park, Jeong Heo, Tae Jin Lee, Hyung Joon Yim, Jong Eun Yeon, Young-Suk Lim, Min Jeong Seo, Sang Hoon Ahn & Myung Seok Lee. (2013) A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options. PLoS ONE 8:3, pages e57900.
Crossref
Crossref
Eun Hye KimHana ParkKun Ho LeeSang Hoon AhnSeung-Min KimKwang-Hyub Han. (2013) Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clinical and Molecular Hepatology 19:1, pages 82.
Crossref
Crossref
En-Qiang Chen, Tao-You Zhou, Lang Bai, Jing-Rong Wang, Li-Bo Yan, Ling-Bo Liang & Hong Tang. (2012) Lamivudine plus Adefovir or Telbivudine plus Adefovir for Chronic Hepatitis B Patients with Suboptimal Response to Adefovir. Antiviral Therapy 17:6, pages 973-979.
Crossref
Crossref
Yuk-Fai Lam, Man-Fung Yuen, Wai-Kay Seto & Ching-Lung Lai. (2011) Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Current Hepatitis Reports 10:4, pages 235-243.
Crossref
Crossref
Wai-Kay Seto, Ching-Lung Lai, James Fung, Danny Ka-Ho Wong, John Chi-Hang Yuen, Ivan Fan-Ngai Hung & Man-Fung Yuen. (2011) Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. Journal of Hepatology 55:3, pages 522-528.
Crossref
Crossref
Michelle Giles, Kumar Visvanathan & Joe Sasadeusz. (2011) Antiviral Therapy for Hepatitis B Infection during Pregnancy and Breastfeeding. Antiviral Therapy 16:5, pages 621-628.
Crossref
Crossref